Chronic ethanol consumption enhances phenylephrine-induced contraction in the isolated rat aorta

J Pharmacol Exp Ther. 2006 Jan;316(1):233-41. doi: 10.1124/jpet.105.092999. Epub 2005 Sep 20.

Abstract

Changes in reactivity to phenylephrine in aortas isolated from 2-, 6-, and 10-week ethanol-treated rats and their age-matched control and isocaloric rats were investigated. Chronic ethanol consumption enhances the contractile response of endothelium-intact and -denuded rat aortic rings to phenylephrine, a response that is time-independent. Pretreatment with indomethacin reduced E(max) for phenylephrine in denuded aortas from ethanol-treated rats but not control or isocaloric rats. After indomethacin treatment, no differences in E(max) from phenylephrine were observed among the groups. SQ29548 ([1S-[1alpha-2alpha(Z)3alpha,4alpha]]-7-[3-[[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid), an antagonist of prostaglandin H(2)/thromboxane A(2) (TXA(2)) receptors, did not alter phenylephrine-induced contraction in control or isocaloric aortas. However, in ethanol-treated aortas, E(max) was reduced to control level. Moreover, phenylephrine-stimulated release of thromboxane B(2), a stable metabolite of TXA(2), was higher in tissues from ethanol-treated rats. Simultaneous measurement of the changes in [Ca(2+)](i) and contraction induced by phenylephrine showed that both parameters are higher in the rat aorta from ethanol-treated rats. CaCl(2)-induced contraction in free Ca(2+) solution containing phenylephrine was increased in ethanol-treated aortas. Additionally, the enhancement in CaCl(2)-induced contraction was prevented by SQ29548. The major contribution of the present study is that it demonstrates a detailed description of the mechanisms involved in the enhancement of phenylephrine-induced contraction in rat aorta from ethanol-treated rats. We provided evidence that this response was not different among the three periods of treatment employed in this study and that it is maintained by two mechanisms: an increased release of vascular smooth muscle-derived vasoconstrictor prostanoids (probably TXA(2)) and an enhanced extracellular Ca(2+) influx.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects*
  • Arachidonic Acid / metabolism
  • Arachidonic Acid / physiology
  • Blood Glucose / metabolism
  • Body Weight / drug effects
  • Calcium / metabolism
  • Cardiotonic Agents / pharmacology*
  • Central Nervous System Depressants / blood
  • Central Nervous System Depressants / pharmacology*
  • Cytosol / drug effects
  • Cytosol / metabolism
  • Dose-Response Relationship, Drug
  • Endothelin-1 / pharmacology
  • Endothelium, Vascular / enzymology
  • Endothelium, Vascular / physiology
  • Ethanol / blood
  • Ethanol / pharmacology*
  • Heart / drug effects*
  • Male
  • Muscle Contraction / drug effects
  • Muscle, Smooth, Vascular / drug effects*
  • Nitric Oxide / physiology
  • Phenylephrine / pharmacology*
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Rats
  • Rats, Wistar
  • Thromboxane A2 / metabolism

Substances

  • Blood Glucose
  • Cardiotonic Agents
  • Central Nervous System Depressants
  • Endothelin-1
  • Phenylephrine
  • Arachidonic Acid
  • Nitric Oxide
  • Ethanol
  • Thromboxane A2
  • Prostaglandin-Endoperoxide Synthases
  • Calcium